Glioblastoma multiforme (GBM) is the most common as well as one of the most malignant types of brain cancer. Despite progress in development of novel therapies for the treatment of GBM, it remains largely incurable with a poor prognosis and a very low life expectancy. Recent studies have shown that oleandrin, a unique cardiac glycoside from Nerium oleander, as well as a defined extract (PBI-05204) that contains this molecule, inhibit growth of human glioblastoma, and modulate glioblastoma patient-derived stem cell-renewal properties. Here we demonstrate that PBI-05204 treatment leads to an increase in vitro in the sensitivity of GBM cells to radiation in which the main mechanisms are the transition from autophagy to apoptosis, enhanced DNA damage and reduced DNA repair after radiotherapy (RT) administration. The combination of PBI-05204 with RT was associated with reduced tumor progression evidenced by both subcutaneous as well as orthotopic implanted GBM tumors. Collectively, these results reveal that PBI-05204 enhances antitumor activity of RT in preclinical/murine models of human GBM. Given the fact that PBI-05204 has already been examined in Phase I and II clinical trials for cancer patients, its efficacy when combined with standard-of-care radiotherapy regimens in GBM should be explored.

The botanical drug PBI-05204, a supercritical CO2 extract of nerium oleander, is synergistic with radiotherapy in models of human glioblastoma / Colapietro, Alessandro; Yang, Peiying; Rossetti, Alessandra; Mancini, Andrea; Vitale, Flora; Chakraborty, Sharmistha; Martellucci, Stefano; Marampon, Francesco; Mattei, Vincenzo; Luca Gravina, Giovanni; Iorio, Roberto; Newman, Robert A.; Festuccia, Claudio. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - 13:(2022). [10.3389/fphar.2022.852941]

The botanical drug PBI-05204, a supercritical CO2 extract of nerium oleander, is synergistic with radiotherapy in models of human glioblastoma

Stefano Martellucci;Francesco Marampon;
2022

Abstract

Glioblastoma multiforme (GBM) is the most common as well as one of the most malignant types of brain cancer. Despite progress in development of novel therapies for the treatment of GBM, it remains largely incurable with a poor prognosis and a very low life expectancy. Recent studies have shown that oleandrin, a unique cardiac glycoside from Nerium oleander, as well as a defined extract (PBI-05204) that contains this molecule, inhibit growth of human glioblastoma, and modulate glioblastoma patient-derived stem cell-renewal properties. Here we demonstrate that PBI-05204 treatment leads to an increase in vitro in the sensitivity of GBM cells to radiation in which the main mechanisms are the transition from autophagy to apoptosis, enhanced DNA damage and reduced DNA repair after radiotherapy (RT) administration. The combination of PBI-05204 with RT was associated with reduced tumor progression evidenced by both subcutaneous as well as orthotopic implanted GBM tumors. Collectively, these results reveal that PBI-05204 enhances antitumor activity of RT in preclinical/murine models of human GBM. Given the fact that PBI-05204 has already been examined in Phase I and II clinical trials for cancer patients, its efficacy when combined with standard-of-care radiotherapy regimens in GBM should be explored.
DNA repair; PBI-05204; apoptosis; glioblastoma; oleandrin; radiotherapy
01 Pubblicazione su rivista::01a Articolo in rivista
The botanical drug PBI-05204, a supercritical CO2 extract of nerium oleander, is synergistic with radiotherapy in models of human glioblastoma / Colapietro, Alessandro; Yang, Peiying; Rossetti, Alessandra; Mancini, Andrea; Vitale, Flora; Chakraborty, Sharmistha; Martellucci, Stefano; Marampon, Francesco; Mattei, Vincenzo; Luca Gravina, Giovanni; Iorio, Roberto; Newman, Robert A.; Festuccia, Claudio. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - 13:(2022). [10.3389/fphar.2022.852941]
File allegati a questo prodotto
File Dimensione Formato  
Colapietro_The botanical_2022.pdf

accesso aperto

Note: https://www.frontiersin.org/articles/10.3389/fphar.2022.852941/full
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 2.96 MB
Formato Adobe PDF
2.96 MB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1635730
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact